Derivative exercise or conversion — not an open-market buy.
Loading…
Reporting person on SEC Form 4
John C Reed
John C Reed is EVP, Innovative Medicine, R&D at Johnson & Johnson. OQRO lists 21 transactions filed with the SEC under this name, the latest on May 4, 2026, each linked to the official Form 4.
EVP, Innovative Medicine, R&D
Disclosures on record
21
Companies involved
1
Disclosure history
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Officer sold
~$7.27MReported value · 30K sh @ $243.00
Stock since the trade +4.0% · S&P 500 +13.5% · to Oct 5
Johnson & Johnson's Innovative Medicine, R&D sold $7.27M of Johnson & Johnson shares. Nobody planned it ahead of time.
Officer sold
~$5.28MReported value · 22K sh @ $243.00
Stock since the trade +4.0% · S&P 500 +13.5% · to Oct 5
Johnson & Johnson's Innovative Medicine, R&D sold $5.28M of Johnson & Johnson shares. Nobody planned it ahead of time.
Officer sold
~$555KReported value · 2,283 sh @ $243.00
Stock since the trade +4.0% · S&P 500 +13.5% · to Oct 5
Johnson & Johnson's Innovative Medicine, R&D sold $555K of Johnson & Johnson shares. Nobody planned it ahead of time.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Officer sold
~$4.19MReported value · 22K sh @ $192.7072
Stock since the trade +30.9% · S&P 500 +16.6% · to Oct 5
Johnson & Johnson's Innovative Medicine, R&D sold $4.19M of Johnson & Johnson shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.